Evidence map›Paper›PMID 41871246›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2026

Unveiling the developmental and tumor-suppressive roles of the p53 variant p53psi.

Chiara Gorrini, Soode Jafari, Gordon Duncan, Bryan Snow, Liam Hendrikse, Louis McLoughlin, Jillian Haight, Andrew Wakeham, Chantal Tobin, Andrew Elia and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Unveiling the developmental and tumor-suppressive roles of the p53 variant p53psi.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Chiara GorriniPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
Soode JafariPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
Gordon DuncanPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
Bryan SnowPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
Liam HendriksePrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
Louis McLoughlinSchool of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds LS2 9JT, United Kingdom.
Jillian HaightPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
Andrew WakehamPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
Chantal TobinPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
Andrew EliaPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
Paramesh RamachandranPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
Rhoda LawPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
Bevan GangPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
Tsai-Ling LuPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
Isabel Morgado-PalacinPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
Annick You-TenPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
Thorsten BergerPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
Raffaella SordellaCold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724.
Tak W MakPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.ORCID 0000-0001-6766-861X

Funding

Canadian Institutes of Health Research (CIHR) N/A
6 · The paper itself

Abstract

Through alternative splicing, the TP53 gene can generate multiple protein isoforms with distinct biochemical properties. The p53psi isoform has been identified as a shorter variant than full-length p53 as it lacks nuclear localization, oligomerization, and part of the DNA binding domains due to the use of an alternative 3' splice site in intron 6. Several TP53-truncating mutations, including those producing p53psi, have been detected in a significant proportion of human tumors. However, the mechanistic roles of these truncated p53 proteins remain poorly understood. Here, we describe the generation and analysis of a genetically engineered mouse model that expresses the p53psi protein in place of the full-length p53 protein. In the C57/BL6J genetic background, mice heterozygous for the targeted p53psi allele (p53

Indexed as

Tumor Suppressor Protein p53Alternative SplicingAnimalsEmbryonic DevelopmentFemaleHumansMaleMiceMice, Inbred C57BLMice, TransgenicProtein IsoformsProtein IsoformsTrp53 protein, mouseTumor Suppressor Protein p53cancerp53 splicing isoformtumor suppression

Identifiers

PMID41871246
PMCPMC13038064

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.